Oklahoma SB1030 prohibits discrimination against 340B entities in prescription drug pricing.
Oklahoma SB1030, the 340B Drug Pricing Nondiscrimination Act, aims to ensure fair prescription drug pricing by prohibiting certain actions against entities participating in the federal 340B drug pricing program. The bill mandates that health insurers, pharmacy benefits managers, and other third-party payors must not reimburse 340B entities at lower rates than non-340B entities, impose different terms or conditions, or interfere with patient choices to receive drugs from 340B entities.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.